The Delaware Supreme Court rejected the legitimacy of expert testimony linking the heartburn drug Zantac to cancer, in a ...

In the latest twist in the ocean of Zantac-related litigation playing out across state courts, drugmakers have notched a key ...

Delaware's highest court ruled on Thursday that patients suing drugmakers GSK, Pfizer, Sanofi and Boehringer Ingelheim cannot ...

Delaware's Supreme Court sides with drugmakers including GSK (GSK) and Pfizer (PFE), rejecting expert testimony linking ...

Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal ...

Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung juries.

Sanofi says it has won an arbitration dispute with Boehringer Ingelheim, in which the latter had tried to protect itself from liabilities that may arise from ongoing litigation over Zantac in the ...

Boehringer Ingelheim, GSK, Pfizer and Sanofi , opens new tab all sold brand name Zantac at various times since it was approved in 1983, and have been named in tens of thousands of lawsuits over ...

The sole defendant in the trial was German drugmaker Boehringer Ingelheim. Three lawsuits related to Zantac had previously gone to trial, all in Illinois, with two verdicts for the defense and one ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.